NCT00778882

Gene Therapy for Chronic Granulomatous Disease in Korea

An Open-label, Uncontrolled, Single Center, Phase I/II Trial to Assess the Safety and Efficacy of Autologous Hematopoietic Stem Cells Transduced With MT-gp91 Retroviral Vector in gp91 Defective Chronic Granulomatous Disease Patients

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Helixmith Co., Ltd. · Industry
• Sex: Male
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of administration of autologous hematopoietic stem cells transduced with MT-gp91 retroviral vector for patients with X-linked chronic granulomatous disease.

Conditions

• Chronic Granulomatous Disease

Interventions

Type	Name	Description
DRUG	VM106	Autologous hematopoietic stem cells with MT-gp91 retroviral vector

Timeline

• Start date: 2007-01-01
• Primary completion: 2008-10-01
• Completion: 2010-10-01
• First posted: 2008-10-24
• Last updated: 2025-09-25

Locations

1 site across 1 country: South Korea